Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.36 |
| ▸ | GCGR | P47871 | 4/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049587 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPTTNKSTNKS2NPC1 | |
| SCHEMBL17626003 | 0.79 | KDM4E (0.41) | NR1H2NR1H3MAPK13GCGRMAPK12 | |
| SCHEMBL2652005 | 0.79 | SMN1; SMN2 (0.38) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL403894 | 0.78 | MTOR (0.43) | NR1H2NR1H3ALDH1A1MAPTNPC1 | |
| SCHEMBL4049207 | 0.77 | ALDH1A1 (0.47) | ALDH1A1METAP2IKBKBMAPTNPC1 | |
| SCHEMBL2651838 | 0.75 | RHEB (0.40) | DGAT1MAPK13GCGRMAPK12MAPK11 | |
| SCHEMBL1119442 | 0.75 | GFER (0.46) | DGAT1TRPV1MAPK13MAPK12MAPK11 | |
| SCHEMBL2651782 | 0.72 | DRD1 (0.42) | ALDH1A1ATMMAPTNPC1RAB9A | |
| SCHEMBL6523713 | 0.72 | SCN2A (0.33) | TRPV1ATMNPC1RAB9A | |
| SCHEMBL1119419 | 0.71 | SCN2A (0.33) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396505-A | Methods of treating inflammation | 维鲁公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-115379835-A | Methods of treating coronavirus | 维鲁公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-114702495-A | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-108473495-B | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | disclosed |
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20080188507-A1 | Novel azole derivatives | MSD K.K. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7365079-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20060111380-A1 | Novel azole derivatives | MSD K.K. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188507-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | DGAT1 3680/4885NR1H2 1157/4885NR1H3 1234/4885 |
| US-20060111380-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | DGAT1 3708/4885NR1H2 1262/4885NR1H3 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.